More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to

 More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely
   Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists

In EU5, Venofer and Sanofi's Ferrlecit/Ferlixit are the Reported Patient Share
Leaders in Hemodialysis, According to a New Report from BioTrends Research

PR Newswire

EXTON, Pa., Oct. 30, 2013

EXTON, Pa., Oct. 30, 2013 /PRNewswire/ --BioTrends Research Group, one of the
world's leading research and advisory firms for specialized biopharmaceutical
issues, finds that, while familiarity with FibroGen/Astellas/AstraZeneca's
FG-4592/ASP1517 is low among surveyed nephrologists in the EU5 (France,
Germany, Italy, Spain and the United Kingdom), close to one-half of EU5
nephrologists report a high interest in learning more about the product after
reviewing a product profile. Surveyed EU5 nephrologists also indicate that 35
percent of their chronic kidney disease-non-dialysis patients and 28 percent
of their dialysis patients are likely candidates for FG-4592/ASP1517, which is
a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in clinical


The report entitled TreatmentTrends^®: Renal Anemia (EU5) 2013 also finds that
Vifor Fresenius Medical Care (FMC) Renal Pharma's Venofer leads in reported
patient share in the hemodialysis setting across the major European markets,
followed by Sanofi's Ferrlecit / Ferlixit. Rockwell Medical's Triferic
(soluble ferric pyrophosphate) is profiled in the report and 95 percent of
surveyed nephrologists report low familiarity with this drug.

The findings also reveal that over 90 percent of surveyed EU5 nephrologists
report low familiarity with Keryx Biopharmaceuticals' Zerenex and Vifor
Fresenius Medical Care's PA21.

"While Zerenex or PA21 are likely to reach the renal market before an oral
HIF-PH inhibitor, if they do reach the market, HIF-PH inhibitors may be a
disruptive change to the erythropoetin stimulating agent (ESA) marketplace,"
said BioTrends Research Group Director Rob Dubman. "In Germany, Italy and
Spain, the study also found the use of ESA biosimilars is increasing as well,
which is a more current market dynamic that will continue to impact branded
ESAs in the near future."

TreatmentTrends^®: Renal Anemia (EU5) 2013 is a syndicated report series,
based on primary market research that provides a comprehensive view of the
current and expected future management of renal anemia (ESAs, oral iron and IV
iron) in patients with chronic kidney disease (stage 3, stage 4, peritoneal
dialysis and hemodialysis). Topics include the percent of patients on each
therapy, patient share, therapy initiation levels, perception of laboratory
values, attribute importance and product performance ratings, sales
representative metrics, transplant eligibility and reaction (familiarity,
interest, and percentage of patients likely to be candidates) to new products
in development. The 2013 wave published in October 2013 and is based on a
study with 204 EU5 nephrologists.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please visit BioTrends is a
Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group

Press spacebar to pause and continue. Press esc to stop.